Ruxolitinib

( DrugBank: Ruxolitinib / KEGG DRUG: Ruxolitinib, Ruxolitinib phosphate )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis1
15Inclusion body myositis1
60Aplastic anemia5
IDDisease name (Link within this page)Number of trials
65Primary immunodeficiency1
228Bronchiolitis obliterans3

13. Multiple sclerosis


Clinical trials : 3,685Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

15. Inclusion body myositis


Clinical trials : 46Drugs : 41 - (DrugBank : 14) / Drug target genes : 14 - Drug target pathways : 130 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

60. Aplastic anemia


Clinical trials : 305Drugs : 328 - (DrugBank : 91) / Drug target genes : 60 - Drug target pathways : 183 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 798Drugs : 585 - (DrugBank : 118) / Drug target genes : 100 - Drug target pathways : 216 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

228. Bronchiolitis obliterans


Clinical trials : 108Drugs : 95 - (DrugBank : 30) / Drug target genes : 34 - Drug target pathways : 158 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries